Fusimab

About

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Fusimab's primary focus in drug discovery?

Fusimab focuses on cancer drug discovery using bi-specific antibodies and antibody toxin fusion proteins for cancer treatment.

What is the basis of Fusimab's technology platform?

Fusimab's platform is based on inclonal technology developed by Professor Itai Benhar at the University of Tel-Aviv. It is designed for the efficient expression and folding of full-length antibodies in bacterial culture.

When was Fusimab founded?

Fusimab was founded in January 2010.

What is Fusimab's current operational status?

Fusimab is currently inactive, as of November 2014.

Where is Fusimab's headquarters located?

Fusimab's headquarters is located in Tel Aviv-Yafo, Israel.

How many employees does Fusimab have?

Fusimab has 6 employees.

What is Fusimab's current funding stage?

Fusimab is in the Pre-Funding stage.

Has Fusimab raised any funding?

According to startupim data, Fusimab has not raised any funding.

What is the primary sector classification for Fusimab?

Fusimab's primary sector classification is Health Tech & Life Sciences.

Sectors & technology

Tags